Mitoxantrone

Clinical Effects of Mitoxantrone

Mitoxantrone has been studied in several clinical trials. These trials have examined how well the drug works to treat MS, prostate cancer, and acute nonlymphocytic leukemia.
 
MS
Clinical studies have shown that mitoxantrone can reduce the number of relapses in people with certain types of MS. For example, in one study, people given this drug for 24 months had an average of 0.4 to 0.7 relapses that required treatment with a corticosteroid, compared with an average of 1.2 relapses in people not given it.
 
Advanced Hormone-Refractory Prostate Cancer
In studies involving men with advanced hormone-refractory prostate cancer (cancer that is not responsive to hormonal treatment), the combination of mitoxantrone and low doses of prednisone reduced pain more than when the low-dose prednisone was used alone.
 
In addition, 38 percent of men who received the combination had a decrease in pain intensity and needed less pain medication, compared with 21 percent of men who receive prednisone alone.
 
Acute Nonlymphocytic Leukemia
In studies looking at the effects of mitoxantrone for treating ANLL, mitoxantrone was compared with a chemotherapy medication known as daunorubicin (Cerubidine®). In one of these studies, 63 percent of people given mitoxantrone had a complete response to the medication, compared with 53 percent of those given daunorubicin. People given mitoxantrone also survived longer (312 days, compared with 237 for those treated with daunorubicin). It should be noted that everyone in the study also received cytarabine (Depocyt®).
 
5 Easy Tips to Manage Visitors During Cancer Treatment

Mitoxantrone Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.